Pharmacoepidemiologic Studies Should Estimate AE Background Rates – FDA
Executive Summary
Pharmacoepidemiologic risk assessment by drug companies should include an estimate of background rates for the adverse event being studied, FDA said in its 1draft concept paper on pharmacovigilance